• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Population-Based Outcomes in NSCLC.非小细胞肺癌基于人群的结局
JNCI Cancer Spectr. 2019 Jun 7;3(3):pkz022. doi: 10.1093/jncics/pkz022. eCollection 2019 Sep.
2
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.表皮生长因子受体突变（EGFR）检测对晚期非小细胞肺癌患者使用表皮生长因子受体靶向酪氨酸激酶抑制剂（TKI）药物疗效的预测：一项循证分析
Ont Health Technol Assess Ser. 2010;10(24):1-48. Epub 2010 Dec 1.
3
Second Primary Non-Small-Cell Lung Cancer After Head and Neck Cancer: A Population-Based Study of Clinical and Pathologic Characteristics and Survival Outcomes in 3597 Patients.头颈部癌后第二原发性非小细胞肺癌：3597 例患者的临床和病理特征及生存结局的基于人群研究。
Clin Lung Cancer. 2020 May;21(3):195-203. doi: 10.1016/j.cllc.2019.02.017. Epub 2019 Mar 4.
4
Non-small-cell lung cancer after breast cancer: a population-based study of clinicopathologic characteristics and survival outcomes in 3529 women.乳腺癌后非小细胞肺癌：3529 例女性患者的临床病理特征和生存结局的基于人群研究。
J Thorac Oncol. 2014 Aug;9(8):1081-90. doi: 10.1097/JTO.0000000000000213.
5
Impact of diabetes on stage I lung cancer treatment patterns and prognosis in older adults: A population-based cohort study.糖尿病对老年人I期肺癌治疗模式和预后的影响：一项基于人群的队列研究。
Heliyon. 2023 Jul 5;9(7):e17969. doi: 10.1016/j.heliyon.2023.e17969. eCollection 2023 Jul.
6
Efficacy of immunotherapy in -mutant advanced NSCLC: A real-world study in a Chinese population.免疫疗法在KRAS突变的晚期非小细胞肺癌中的疗效：一项针对中国人群的真实世界研究。
Front Oncol. 2023 Jan 19;12:1070761. doi: 10.3389/fonc.2022.1070761. eCollection 2022.
7
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.一线帕博利珠单抗治疗 PD-L1≥50%的 IV 期 NSCLC 的真实世界结局：二线系统治疗的应用。
Curr Oncol. 2023 May 26;30(6):5299-5308. doi: 10.3390/curroncol30060402.
8
Variables affecting survival after second primary lung cancer: A population-based study of 187 Hodgkin's lymphoma patients.影响第二原发性肺癌患者生存的因素：基于人群的 187 例霍奇金淋巴瘤患者研究。
J Thorac Dis. 2012 Feb;4(1):22-9. doi: 10.3978/j.issn.2072-1439.2011.12.02.
9
Comorbidities and relevant outcomes, commonly associated with cancer, of patients newly diagnosed with advanced non-small-cell lung cancer in Sweden.瑞典新诊断为晚期非小细胞肺癌患者的合并症及相关结局，这些合并症通常与癌症相关。
Eur J Cancer Care (Engl). 2020 Jan;29(1):e13171. doi: 10.1111/ecc.13171. Epub 2019 Oct 2.
10
EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.非小细胞肺癌中 EGFR 外显子 20 插入与铂类化疗的反应。
Clin Lung Cancer. 2022 Mar;23(2):e148-e153. doi: 10.1016/j.cllc.2021.07.001. Epub 2021 Jul 19.

本文引用的文献

1
First-Line Systemic Treatments for Stage IV Non-Small Cell Lung Cancer in California: Patterns of Care and Outcomes in a Real-World Setting.加利福尼亚州IV期非小细胞肺癌的一线全身治疗：真实世界中的治疗模式与结局
JNCI Cancer Spectr. 2019 Apr 4;3(3):pkz020. doi: 10.1093/jncics/pkz020. eCollection 2019 Sep.
2
Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States.美国学术中心与社区中心 IV 期肺癌患者的生存比较。
J Thorac Oncol. 2018 Dec;13(12):1842-1850. doi: 10.1016/j.jtho.2018.09.007. Epub 2018 Oct 9.
3
Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622).对于非小细胞肺癌的老年患者，一线基于铂类的双联化疗是否也有益？来自 730 例前瞻性治疗患者（Alliance 研究 A151622）的汇总分析观察结果。
J Geriatr Oncol. 2018 Sep;9(5):501-506. doi: 10.1016/j.jgo.2018.05.006. Epub 2018 May 27.
4
Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study.对具有不确定获益的上市药品进行监管撤市：贝伐单抗案例研究
J Pharm Policy Pract. 2015 Oct 19;8:25. doi: 10.1186/s40545-015-0046-2. eCollection 2015.
5
Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?真实世界中转移性非小细胞肺癌的化疗治疗模式：患者是否治疗不足？
Cancer. 2015 Aug 1;121(15):2562-9. doi: 10.1002/cncr.29386. Epub 2015 Apr 17.
6
Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.肺癌主方案（Lung-MAP）——一种由生物标志物驱动的加速鳞状细胞肺癌治疗药物研发的方案：SWOG S1400
Clin Cancer Res. 2015 Apr 1;21(7):1514-24. doi: 10.1158/1078-0432.CCR-13-3473. Epub 2015 Feb 13.
7
50 Years of progress in the systemic therapy of non-small cell lung cancer.非小细胞肺癌全身治疗50年的进展
Am Soc Clin Oncol Educ Book. 2014:177-89. doi: 10.14694/EdBook_AM.2014.34.177.
8
Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.非小细胞肺癌组织学亚型的化疗结果：抗微管-铂类治疗的西南肿瘤学组数据库分析。
Clin Lung Cancer. 2013 Nov;14(6):627-35. doi: 10.1016/j.cllc.2013.06.010. Epub 2013 Jul 31.
9
Comprehensive genomic characterization of squamous cell lung cancers.全面基因组特征分析鳞状细胞肺癌
Nature. 2012 Sep 27;489(7417):519-25. doi: 10.1038/nature11404. Epub 2012 Sep 9.
10
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.卡铂和每周紫杉醇联合化疗与单药治疗老年晚期非小细胞肺癌的比较：IFCT-0501 随机、3 期试验。
Lancet. 2011 Sep 17;378(9796):1079-88. doi: 10.1016/S0140-6736(11)60780-0. Epub 2011 Aug 8.

Population-Based Outcomes in NSCLC.

作者信息

Edelman Martin J

机构信息

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA.

出版信息

JNCI Cancer Spectr. 2019 Jun 7;3(3):pkz022. doi: 10.1093/jncics/pkz022. eCollection 2019 Sep.

DOI:10.1093/jncics/pkz022
PMID:32328552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7050018/
Abstract
摘要